Acute Erythroblastic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells.
|
7828582 |
1995 |
Adult Erythroleukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells.
|
7828582 |
1995 |
Erythroleukemia (Erythroid/Myeloid)
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells.
|
7828582 |
1995 |
Liver Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the frequency of C2 allele of cytochrome P45 02E1 was found to be higher in patients with nonfibrotic alcoholic liver disease than in patients with severe hepatic fibrosis or liver cirrhosis.
|
9211568 |
1997 |
Alcoholic Liver Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, the frequency of C2 allele of cytochrome P45 02E1 was found to be higher in patients with nonfibrotic alcoholic liver disease than in patients with severe hepatic fibrosis or liver cirrhosis.
|
9211568 |
1997 |
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the frequency of C2 allele of cytochrome P45 02E1 was found to be higher in patients with nonfibrotic alcoholic liver disease than in patients with severe hepatic fibrosis or liver cirrhosis.
|
9211568 |
1997 |
Thrombocytopenia
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These findings implicate the combination of megakaryocytes and the latter particles as a sink for circulating Tpo in NF-E2 knockout mice, and provide an explanation for the lack of elevated serum Tpo levels in this unique animal model of thrombocytopenia.
|
9292514 |
1997 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver.
|
10891470 |
2000 |
Adult Erythroleukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver.
|
10891470 |
2000 |
Erythroleukemia (Erythroid/Myeloid)
|
0.050 |
Biomarker
|
disease |
BEFREE |
Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver.
|
10891470 |
2000 |
Thrombocythemia, Essential
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although real-time RT-PCR showed that both a and f NF-E2 isoforms were significantly reduced with respect to the normal counterpart both in ET megakaryocytes and in cell lines (P < or = 0.01), western blotting revealed decreased NF-E2 protein expression only in the latter.
|
12200693 |
2002 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Retroviral insertional activation of Fli-1 and Spi-1/PU.1, as well as loss of tumour suppressor genes such as p53 or p45 NFE2 have been shown to be critical for the induction and progression of Friend virus-induced erythroleukemias.
|
12894591 |
2003 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Retroviral insertional activation of Fli-1 and Spi-1/PU.1, as well as loss of tumour suppressor genes such as p53 or p45 NFE2 have been shown to be critical for the induction and progression of Friend virus-induced erythroleukemias.
|
12894591 |
2003 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells.
|
14597626 |
2004 |
Adult Erythroleukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells.
|
14597626 |
2004 |
Erythroleukemia (Erythroid/Myeloid)
|
0.050 |
Biomarker
|
disease |
BEFREE |
The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells.
|
14597626 |
2004 |
Polycythemia Vera
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
One Sp1 target, the transcription factor NF-E2 [nuclear factor (erythroid-derived 2)], is overexpressed 2- to 40-fold in PV patients.
|
15801966 |
2005 |
Thrombocytosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this model, the level of NF-E2 overexpression determines both the severity of erythrocytosis and the concurrent presence or absence of thrombocytosis.
|
15801966 |
2005 |
Mycoplasma Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
This is the first demonstration that Mycoplasma fermentans, in infecting human B cells, generates a p45 Mycoplasma component that interacts with CD21, which is involved in B cell proliferation.
|
16054780 |
2005 |
Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients.
|
16081684 |
2005 |
Septicemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (G-CSF) treatment.
|
16081684 |
2005 |
Sepsis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (G-CSF) treatment.
|
16081684 |
2005 |
Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
They include one patient with PV and +9p with three copies of JAK2 and two patients with MDS and JAK2 relocations: one with NF-E2, while the other patient with a TEL/ETV6 rearrangements also had tetrasomy for JAK2.
|
17976519 |
2007 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Isothiocyanates and phenolic antioxidants can prevent cancer through activation of Nrf2 (NF-E2 p45-related factor 2), a transcription factor that controls expression of cytoprotective genes through the antioxidant response element (ARE) enhancer.
|
18048326 |
2007 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Isothiocyanates and phenolic antioxidants can prevent cancer through activation of Nrf2 (NF-E2 p45-related factor 2), a transcription factor that controls expression of cytoprotective genes through the antioxidant response element (ARE) enhancer.
|
18048326 |
2007 |